CoChat

mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus

Petrasek, Tomas, Vojtechova, Iveta, Klovrza, Ondrej, Tuckova, Klara, Vejmola, Cestmir, Rak, Jakub, Sulakova, Anna, Kaping, Daniel, Bernhardt, Nadine, de Vries, Petrus J., Otahal, Jakub, Waltereit, Robert · 2021 · Journal of Neurodevelopmental Disorders

Published version of a preprint

Cited by 30

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: Tuberous sclerosis complex (TSC), a multi-system genetic disorder often associated with autism spectrum disorder (ASD), is caused by mutations of TSC1 or TSC2 , which lead to constitutive overactivation of mammalian target of rapamycin (mTOR). In several Tsc1+/- and Tsc2+/- animal models, cognitive and social behavior deficits were reversed by mTOR inhibitors. However, phase II studies have not shown amelioration of ASD and cognitive deficits in individuals with TSC during mTOR inhibitor therapy. We asked here if developmental epilepsy, common in the majority of individuals with TSC but absent in most animal models, could explain the discrepancy. Methods: At postnatal day P12, developmental status epilepticus (DSE) was induced in male Tsc2+/- (Eker) and wild-type rats, establishing four experimental groups including controls. In adult animals ( n = 36), the behavior was assessed in the paradigms of social interaction test, elevated plus-maze, light-dark test, Y-maze, and novel object recognition. The testing was carried out before medication (T1), during a 2-week treatment with the mTOR inhibitor everolimus (T2) and after an 8-week washing-out (T3). Electroencephalographic (EEG) activity was recorded in a separate set of animals ( n = 18). Results: Both Tsc2+/- mutation and DSE caused social behavior deficits and epileptiform EEG abnormalities (T1). Everolimus led to a persistent improvement of the social deficit induced by Tsc2+/- , while deficits related to DSE did not respond to everolimus (T2, T3). Conclusions: These findings may contribute to an explanation why ASD symptoms in individuals with TSC, where comorbid early-onset epilepsy is common, were not reliably ameliorated by mTOR inhibitors in clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s11689-021-09357-2

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 73

  1. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges. Neuropsychiatr Dis Treat. 2018;14:1–10. · DOI · Paper page
  2. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P, et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol Psychiatry. 2008;64:577–82. · DOI · Paper page
  3. Reilly C, Atkinson P, Das KB, Chin RFMC, Aylett SE, Burch V, et al. Neurobehavioral comorbidities in children with active epilepsy: a population-based study. Pediatrics. 2014;133:e1586–93. · DOI · Paper page
  4. de Vries PJ, Prather PA. The tuberous sclerosis complex. N Engl J Med. 2007;356:92. · DOI · Paper page
  5. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord. 1998;28:407–14. · DOI · Paper page
  6. Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain. 2002;125:1247–55. · DOI · Paper page
  7. Wu JY, Peters JM, Goyal M, Krueger D, Sahin M, Northrup H, et al. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016;54:29–34. · DOI · Paper page
  8. Kotulska K, Kwiatkowski DJ, Curatolo P, Weschke B, Riney K, Jansen F, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89:304–14. · DOI · Paper page
  9. Davis PE, Kapur K, Filip-Dhima R, Trowbridge SK, Little E, Wilson A, et al. Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex. Epilepsia. 2019;60:1721–32. · DOI
  10. Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study. Epilepsia Open. 2019;4:73–84. · DOI · Paper page
  11. Capal JK, Bernardino-Cuesta B, Horn PS, Murray D, Byars AW, Bing NM, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70:245–52. · DOI · Paper page
  12. Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, et al. Epilepsy treatment patterns among patients with tuberous sclerosis complex. J Neurol Sci. 2018;391:104–8. · DOI
  13. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817–24. · DOI · Paper page
  14. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125–32. · DOI · Paper page
  15. Sasongko TH, Ismail NFD, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev. 2016;7:CD011272.
  16. de Vries PJ, Howe CJ. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment. Trends Mol Med. 2007;13:319–26. · DOI · Paper page
  17. Sato A, Kasai S, Kobayashi T, Takamatsu Y, Hino O, Ikeda K, et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun. 2012;3:1292. · DOI · Paper page
  18. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–81. · DOI · Paper page
  19. Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, ten Hoopen LW, et al. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology. 2019;93:e200–9. · DOI · Paper page
  20. Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Marechal K, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med. 2015;45:2321–31. · DOI
  21. Jansen FE, Vincken KL, Algra A, Anbeek P, Braams O, Nellist M, et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology. 2008;70:916–23. · DOI · Paper page
  22. Humphrey A, MacLean C, Ploubidis GB, Granader Y, Clifford M, Haslop M, et al. Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis. Epilepsia. 2014;55:108–16. · DOI
  23. Jeste SS, Sahin M, Bolton P, Ploubidis GB, Humphrey A. Characterization of autism in young children with tuberous sclerosis complex. J Child Neurol. 2008;23:520–5. · DOI · Paper page
  24. Numis AL, Major P, Montenegro MA, Muzykewicz DA, Pulsifer MB, Thiele EA. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology. 2011;76:981–7. · DOI · Paper page
  25. Vignoli A, La Briola F, Peron A, Turner K, Vannicola C, Saccani M, et al. Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers. Orphanet J Rare Dis. 2015;10:154. · DOI
  26. Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology. 2005;65:235–8. · DOI
  27. O’Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004;89:530–3. · DOI · Paper page
  28. Primec ZR, Stare J, Neubauer D. The risk of lower mental outcome in infantile spasms increases after three weeks of hypsarrhythmia duration. Epilepsia. 2006;47:2202–5. · DOI
  29. Riikonen R, Amnell G. Psychiatric disorders in children with earlier infantile spasms. Dev Med Child Neurol. 1981;23:747–60. · DOI · Paper page
  30. von der Brelie C, Waltereit R, Zhang L, Beck H, Kirschstein T. Impaired synaptic plasticity in a rat model of tuberous sclerosis. Eur J Neurosci. 2006;23:686–92. · DOI · Paper page
  31. Waltereit R, Welzl H, Dichgans J, Lipp H-P, Schmidt WJ, Weller M. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem. 2006;96:407–13. · DOI · Paper page
  32. Waltereit R, Japs B, Schneider M, de Vries PJ, Bartsch D. Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats. Behav Genet. 2011;41:364–72. · DOI · Paper page
  33. Schneider M, de Vries PJ, Schönig K, Rößner V, Waltereit R. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus. Eur Arch Psychiatry Clin Neurosci. 2017;267(5):455–63. · DOI · Paper page
  34. Young DM, Schenk AK, Yang S-B, Jan YN, Jan LY. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc Natl Acad Sci U S A. 2010;107:11074–9. · DOI · Paper page
  35. Rennebeck G, Kleymenova EV, Anderson R, Yeung RS, Artzt K, Walker CL. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc Natl Acad Sci U S A. 1998;95:15629–34. · DOI · Paper page
  36. Kútna V, Uttl L, Waltereit R, Krištofiková Z, Kaping D, Petrásek T, et al. Tuberous sclerosis (tsc2+/-) model Eker rats reveals extensive neuronal loss with microglial invasion and vascular remodeling related to brain neoplasia. Neurotherapeutics. 2019;17:329–39. · DOI · Paper page
  37. Mikulecká A, Druga R, Stuchlík A, Mareš P, Kubová H. Comorbidities of early-onset temporal epilepsy: cognitive, social, emotional, and morphologic dimensions. Exp Neurol. 2019;320:113005. · DOI
  38. Druga R, Mares P, Otáhal J, Kubová H. Degenerative neuronal changes in the rat thalamus induced by status epilepticus at different developmental stages. Epilepsy Res. 2005;63:43–65. · DOI
  39. Kubova H, Mares P. Are morphologic and functional consequences of status epilepticus in infant rats progressive? Neuroscience. 2013;235:232–49. · DOI
  40. Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, Betto G, et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis. 2009;33:171–81. · DOI · Paper page
  41. Lynch M, Sayin U, Bownds J, Janumpalli S, Sutula T. Long-term consequences of early postnatal seizures on hippocampal learning and plasticity. Eur J Neurosci. 2000;12:2252–64. · DOI · Paper page
  42. Sayin U, Sutula TP, Stafstrom CE. Seizures in the developing brain cause adverse long-term effects on spatial learning and anxiety. Epilepsia. 2004;45:1539–48. · DOI
  43. Dulla CG. Utilizing animal models of infantile spasms. Epilepsy Curr. 2018;18:107–12. · DOI
  44. Stafstrom CE. Infantile spasms: a critical review of emerging animal models. Epilepsy Curr. 2009;9:75–81. · DOI
  45. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav. 1994;49:171–6. · DOI · Paper page
  46. Griebel G, Rodgers RJ, Perrault G, Sanger DJ. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav. 1997;57:817–27. · DOI · Paper page
  47. Arrant AE, Schramm-Sapyta NL, Kuhn CM. Use of the light/dark test for anxiety in adult and adolescent male rats. Behav Brain Res. 2013;256:119–27. · DOI · Paper page
  48. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. Cambridge: Academic Press; 2007.
  49. Friard O, Gamba M. BORIS: a free, versatile open-source event-logging software for video/audio coding and live observations. Methods Ecol Evol. 2016;7:1325–30. · DOI · Paper page
  50. de Oliveira DL, Fischer A, Jorge RS, da Silva MC, Leite M, Goncalves CA, et al. Effects of early-life LiCl-pilocarpine-induced status epilepticus on memory and anxiety in adult rats are associated with mossy fiber sprouting and elevated CSF S100B protein. Epilepsia. 2008;49:842–52. · DOI
  51. Castelhano ASS, Scorza FA, Teixeira MCTV, Arida RM, Cavalheiro EA, Cysneiros RM. Social play impairment following status epilepticus during early development. J Neural Transm. 2010;117:1155–60. · DOI
  52. Petrasek T, Vojtechova I, Lobellova V, Popelikova A, Janikova M, Brozka H, et al. The McGill transgenic rat model of Alzheimer’s disease displays cognitive and motor impairments, changes in anxiety and social behavior, and altered circadian activity. Front Aging Neurosci. 2018;10:1–23. · DOI
  53. Moura PJ, Meirelles ST, Xavier GF. Long-term social recognition memory in adult male rats: factor analysis of the social and non-social behaviors. Braz J Med Biol Res. 2010;43:663–76. · DOI
  54. Chevere-Torres I, Maki JM, Santini E, Klann E. Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin. Neurobiol Dis. 2012;45:156–64. · DOI
  55. Yuan E, Tsai PT, Greene-Colozzi E, Sahin M, Kwiatkowski DJ, Malinowska IA. Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features. Hum Mol Genet. 2012;21:4286–300. · DOI
  56. Kubova H, Mares P, Suchomelova L, Brozek G, Druga R, Pitkanen A. Status epilepticus in immature rats leads to behavioural and cognitive impairment and epileptogenesis. Eur J Neurosci. 2004;19:3255–65. · doi:10.1111/j.0953-816x.2004.03410.x
  57. Loss CM, Cordova SD, de Oliveira DL. Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. Brain Res. 2012;1474:110–7. · DOI
  58. Castelhano ASS, Cassane GDST, Scorza FA, Cysneiros RM. Altered anxiety-related and abnormal social behaviors in rats exposed to early life seizures. Front Behav Neurosci. 2013;7:1–8. · DOI
  59. Detour J, Schroeder H, Desor D, Nehlig A. A 5-month period of epilepsy impairs spatial memory, decreases anxiety, but spares object recognition in the lithium-pilocarpine model in adult rats. Epilepsia. 2005;46:499–508. · DOI · Paper page
  60. Ehninger D, Silva AJ. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav Genet. 2011;41:357–63. · DOI
  61. File SE. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res. 2001;125:151–7. · DOI · Paper page
  62. Cornejo BJ, Mesches MH, Benke TA. A single early-life seizure impairs short-term memory but does not alter spatial learning, recognition memory, or anxiety. Epilepsy Behav. 2008;13:585–92. · DOI
  63. Takahashi DK, Dinday MT, Barbaro NM, Baraban SC. Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex. Epilepsia. 2004;45:1525–30. · DOI · Paper page
  64. Wenzel HJ, Patel LS, Robbins CA, Emmi A, Yeung RS, Schwartzkroin PA. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Acta Neuropathol. 2004;108:97–108. · DOI
  65. Tschuluun N, Wenzel HJ, Schwartzkroin PA. Irradiation exacerbates cortical cytopathology in the Eker rat model of tuberous sclerosis complex, but does not induce hyperexcitability. Epilepsy Res. 2007;73:53–64. · DOI
  66. Rondouin G, Lerner-Natoli M, Hashizume A. Wet dog shakes in limbic versus generalized seizures. Exp Neurol. 1987;95:500–5. · doi:10.1016/0014-4886(87)90156-7
  67. Priel MR, dos Santos NF, Cavalheiro EA. Developmental aspects of the pilocarpine model of epilepsy. Epilepsy Res. 1996;26:115–21. · DOI · Paper page
  68. Taylor JA, Reuter JD, Kubiak RA, Mufford TT, Booth CJ, Dudek FE, et al. Spontaneous recurrent absence seizure-like events in wild-caught rats. J Neurosci. 2019;39:4829–41. · DOI
  69. Ben-Ari Y, Represa A. Brief seizure episodes induce long-term potentiation and mossy fibre sprouting in the hippocampus. Trends Neurosci. 1990;13:312–8. · DOI · Paper page
  70. Moavero R, Benvenuto A, Emberti Gialloreti L, Siracusano M, Kotulska K, Weschke B, et al. Early clinical predictors of autism spectrum disorder in infants with tuberous sclerosis complex: results from the EPISTOP study. J Clin Med. 2019;8:788. · DOI
  71. Jozwiak S, Kotulska K, Wong M, Bebin M. Modifying genetic epilepsies - results from studies on tuberous sclerosis complex. Neuropharmacology. 2019;166:107908. · DOI
  72. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1:352–8. · DOI · Paper page
  73. Howe CJ, Serfontein J, Nisbet ER, de Vries PJ. Viewing animal models for tuberous sclerosis complex in the light of evolution. In: Roubertoux PL, editor. Org Model Autism Spectr Disord. New York: Humana Press; 2015. p. 99–115. · DOI

Cited by

See all 30

Metadata

Authors
Petrasek, T., Vojtechova, I., Klovrza, O., Tuckova, K., Vejmola, C., Rak, J., Sulakova, A., Kaping, D., Bernhardt, N., de Vries, P. J., Otahal, J., & Waltereit, R.
Venue
Journal of Neurodevelopmental Disorders
Published
2021-04-17
Volume
13
Issue
1
ISSN
  • 1866-1947
  • 1866-1955
Cited by
30
References
10
Language
en
Licence
Funders
  • German Tuberous Sclerosis Foundation (personal unrestricted grant)
  • Novartis Pharma (investigator-initiated research support)
  • Ministry of Education, Youth and Sports of the Czech Republic (LO1611)
  • Georg-August-Universität Göttingen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. https://app.cochat.ai/papers/10.1186/s11689-021-09357-2
The paper
Petrasek, T., Vojtechova, I., Klovrza, O., Tuckova, K., Vejmola, C., Rak, J., Sulakova, A., Kaping, D., Bernhardt, N., de Vries, P. J., Otahal, J., & Waltereit, R. (2021). mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. Journal of Neurodevelopmental Disorders. https://doi.org/10.1186/s11689-021-09357-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.